The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
NCRI 2016 | Next steps for the CONVERT trial in LS-SCLC
Corinne Faivre-Finn, FRCR, MD, PhD of University of Manchester and the Christie NHS Foundation Trust, UK discusses next steps for the CONVERT trial in limited-stage small-cell lung cancer (LS-SCLC). Biomarker data collected as part of the clinical trial need to be analyzed to further understand their role as prognostic markers in LS-SCLC. Dr Faivre-Finn highlights that data on the role of circulating tumor cells are going to be reported at the World Conference on Lung Cancer in Vienna in December 2016. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.
